Trendlines sustains profitability and increases portfolio company value

- The Group recorded net profit of US$2.2 million in H1 2026, compared to a loss of US$3.5 million in H1 2025.

- IFRS Portfolio Fair Value: US$83.4 million, compared to US$76.5 million as at 31 December 2025, representing a 9% increase in value; non-IFRS Portfolio Fair Value: US$146.0 million, compared to US$127.7 million as at 31 December 2025, representing a 14% increase in value

- Portfolio companies continue to achieve commercial and fundraising milestones, highlighting their innovation and potential as we position ourselves for long-term value creation and strategic exits.

Misgav, Israel and Singapore, 5 August 2026 – The Trendlines Group Ltd. (the "**Company**" and together with its subsidiaries, "**Trendlines**" or the "**Group**"), the Israel- and Singapore-based company focused on building value through innovation-based medical and agrifood technologies, announced its results for the six months ended 30 June 2026 ("**H1 2026**") today.

Management Commentary

Commenting on H1 2026 results, Haim Brosh, Trendlines' Chief Executive Officer, said, "We delivered growth and profitability across the Group in H1 2026, continuing our upward turnaround trajectory.

We are deeply grateful for the unwavering support of our shareholders, whose commitment to our fundraising efforts has been vital. Raising capital for Trendlines enables us to raise funds for our portfolio companies at higher valuations, which in turn drives valuation gains and supports their continued growth. As our portfolio continues to hit commercial and fundraising milestones, we remain focused on positioning our companies for strategic exits and delivering long-term value for all stakeholders."

Financial Overview

Profit or Loss Highlights (US$'000)	H1 2026	H1 2025
Total Income	5,910	640
Income/(loss) before Tax	2,157	(3,554)
Net Income Attributable to Equity Holders of the Company	2,152	(3,232)
Basic and Diluted Earnings/(Loss) per Share (US cents)	0.15	(0.30)

In H1 2026, the Group saw a net gain of US$5.6 million in the fair value of Portfolio Companies. An increase of approximately US$6.7 million was due to the first-time valuation of the Singapore portfolio companies following the Company's transition to investment entity accounting, under which these investments are now measured at fair value. In addition, there was an increase of approximately US$3.1 million in fair value due to favourable fundraising terms and commercial or technological progress. This increase was partly offset by a US$1.0 million decline in fair value arising from less favourable fundraising terms and commercial challenges at certain Portfolio Companies. Furthermore, seven Portfolio Companies were written off during the period due to a lack of funding, reducing fair value by US$3.2 million.

Balance Sheet Highlights (US$ '000)	30-June-26	31-Dec-25	Change (%)
Investments in portfolio companies	83,406	76,454	9.09
Cash and cash equivalents and short-term deposits	5,013	4,927	1.75
Total current assets	6,563	7,377	(11.03)
Total assets	91,618	85,809	6.77
Total current liabilities	2,912	4,775	(39.02)
Total liabilities	6,586	8,456	(22.11)
Total equity	85,032	77,353	9.93
Net asset value per share (US$)	0.06	0.06	-

Total assets increased by approximately 6.77% from US$85.8 million as at 31 December 2025 to US$91.6 million as at 30 June 2026. This was mainly due to an increase in investments in portfolio companies.

OUR PORTFOLIO CLUSTERS – IFRS FAIR VALUES VS NON-IFRS FAIR VALUES*

Cluster	Fair Value of Trendlines' Share (US$'000)	Non-IFRS Value of Trendlines' Share (additional information) (US$'000)	Fair Value of Trendlines' Share (US$'000)	Non-IFRS Value of Trendlines' Share (additional information) (US$'000)
	30 June 2026		**31 December 2025**	
Aquaculture & Animal Health	1,336	1,492	1,247	2,261
Crop Protection	5,860	11,428	5,747	11,589
Future Food & Ingredients	15,426	26,696	12,831	20,335
Digitization & Robotics	3,473	4,684	3,873	5,084
Net-Zero Technologies	3,409	3,409	4,906	6,051
Cardiology, Neurology & Anesthesia	8,590	16,055	6,422	12,057
Aesthetics	2,661	6,095	2,611	6,318
Gastroenterology	10,524	14,361	10,219	10,516
Home Healthcare	1,138	3,467	2,244	9,267
Spine & Orthopedics	5,877	11,590	5,290	8,554
Surgery	6,154	11,797	4,501	5,031
Urology & Women's Health	18,958	34,926	16,563	30,684
TOTAL	**83,406**	**146,000**	**76,454**	**127,749**

Corporate Developments in H1 2026

- Trendlines raised gross proceeds of approximately S$5.6 million (net proceeds of approximately S$5.4 million) via a private placement to institutional and other investors, completed in January 2026.
- Trendlines and Librae Holdings made investments in portfolio companies.
- Trendlines deconsolidated the Singapore portfolio companies following the Company's transition to investment entity accounting.

Portfolio Companies Developments in H1 2026

- Phytolon Ltd. announced significant progress in the U.S. Food and Drug Administration ("FDA") approval of its Beetroot Red food dye. Phytolon also closed a US$23.6 million Series B fundraising round.
- IBI Ag Ltd. announced the completion of its proof of concept for the AI-driven platform for De Novo design of novel bioinsecticide proteins.
- Celleste Bio Ltd. unveiled the world's first chocolate-grade cocoa butter produced using plant cell culture technology.
- Limaca Medical Ltd. signed a distribution agreement with a multinational medical company for sales of its product in the United States.
- Vensica Medical Ltd. announced that the FDA has cleared the Company's Investigational New Drug ("IND") application to initiate a Phase 2 clinical trial.
- Escala Medical Ltd. expanded its sales in the US and is preparing for sales in Asia.

Post H1 2026 Developments

- ElastiMed Ltd. has entered into an exclusive U.S. distribution agreement with Tactile Systems Technology, Inc., a Nasdaq-listed medical technology company (Nasdaq: TCMD).
- NICE Surgical Pte Ltd. received two US patents for its purse-string stapler.

For full financial information, please see our announcement to the SGX: Unaudited Financial Statements for the Half Year Ended 30 June 2026.

* **For full explanations on NON-IFRS VALUES, please refer to** [our announcement on 7 March 2023.]

About The Trendlines Group Ltd.

Trendlines invests in innovation-based medical and agrifood technologies. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

-The End-

*This press release has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Investor Contact Information

Israel:
Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore:
Kamal Samuel, Financial PR
kamal@financialpr.com.sg
Rishika Tiwari, Financial PR
rishika@financialpr.com.sg
Tel: +65.6438.2990